Japan Tissue Engineering Co., Ltd. (JP:7774) has released an update.
Japan Tissue Engineering Co., Ltd. has completed a clinical trial for its new allogeneic cultured epidermis product, Allo-JaCE03, showing significant improvements in epithelialization rates for deep dermal burns without adverse events. The product, which can be mass-produced and stored at room temperature, represents a new step in regenerative medicine, with plans to seek marketing approval swiftly. This advancement could simplify burn treatment and is poised for both domestic and international distribution.
For further insights into JP:7774 stock, check out TipRanks’ Stock Analysis page.
